Aberdeen Group
CPRX

Aberdeen Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Aberdeen Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-297,512
Closed -$7.37M – 945
2026
Q1 		$7.37M Sell
297,512
-90,398
-23% -$2.15M 0.01% 638
2025
Q4 		$9.05M Sell
387,910
-244,531
-39% -$5.45M 0.01% 625
2025
Q3 		$12.5M Sell
632,441
-56,319
-8% -$1.16M 0.02% 564
2025
Q2 		$14.9M Sell
688,760
-76,534
-10% -$1.81M 0.03% 494
2025
Q1 		$18.6M Buy
765,294
+280,628
+58% +$6.32M 0.04% 414
2024
Q4 		$10.1M Buy
+484,666
New +$10.4M 0.02% 508

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aberdeen Group's CPRX Position: Q2 2026 in Review

Aberdeen Group sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 297,512 shares — an estimated $7.37M sold.

Aberdeen Group first reported a position in CPRX in Q4 2024 and held it in 6 quarters. The position peaked at $18.6M in Q1 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Aberdeen Group reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Aberdeen Group sold 297,512 Catalyst Pharmaceutical shares in Q2 2026, an estimated $7.37M.
  • Aberdeen Group first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 6 quarters.
  • Aberdeen Group's Catalyst Pharmaceutical position peaked at $18.6M in Q1 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.